Chantal Csajka

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi request reprint Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients
    C Csajka
    Division of Clinical Pharmacology, University Hospital, CHUV, Lausanne, Switzerland
    Eur J Clin Pharmacol 57:723-7. 2001
  2. ncbi request reprint Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Clin Pharmacokinet 41:137-52. 2002
  3. ncbi request reprint Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Clin Pharmacol Ther 73:20-30. 2003
  4. pmc Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours
    Amina Haouala
    Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Br J Clin Pharmacol 75:1007-18. 2013
  5. doi request reprint Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals
    Rubin Lubomirov
    Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 23:9-18. 2013
  6. doi request reprint ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
    Rubin Lubomirov
    Institute of Microbiology, Service of Infectious Diseases, Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 20:217-30. 2010
  7. pmc Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
    Sara Colombo
    Division of Clinical Pharmacology and Toxicology, University Hospital, CHUV, Lausanne 1011, Switzerland
    Antimicrob Agents Chemother 50:3801-8. 2006
  8. pmc Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, CHUV, Beaumont 633, Lausanne 1011, Switzerland
    Antimicrob Agents Chemother 48:3226-32. 2004
  9. doi request reprint Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes
    Verena Gotta
    Division of Clinical Pharmacology, Service of Biomedicine, Department of Laboratories, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, Lausanne, Switzerland
    Ther Drug Monit 35:150-67. 2013
  10. pmc Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals
    Mona Arab-Alameddine
    Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    Antimicrob Agents Chemother 56:2959-66. 2012

Collaborators

Detail Information

Publications20

  1. ncbi request reprint Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients
    C Csajka
    Division of Clinical Pharmacology, University Hospital, CHUV, Lausanne, Switzerland
    Eur J Clin Pharmacol 57:723-7. 2001
    ....
  2. ncbi request reprint Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Clin Pharmacokinet 41:137-52. 2002
    ..To compare the pharmacokinetic and pharmacodynamic characteristics of angiotensin II receptor antagonists as a therapeutic class...
  3. ncbi request reprint Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
    Clin Pharmacol Ther 73:20-30. 2003
    ....
  4. pmc Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours
    Amina Haouala
    Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Br J Clin Pharmacol 75:1007-18. 2013
    ..In this study, free and total imatinib concentrations were measured to establish a model allowing the confident prediction of imatinib free concentrations based on total concentrations and plasma proteins measurements...
  5. doi request reprint Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals
    Rubin Lubomirov
    Institute of Microbiology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 23:9-18. 2013
    ..To identify the potential impact of genetic and non-genetic factors involved in ETV metabolism, we carried out a two-step pharmacogenetics-based population pharmacokinetic study in HIV-1 infected individuals...
  6. doi request reprint ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
    Rubin Lubomirov
    Institute of Microbiology, Service of Infectious Diseases, Division of Clinical Pharmacology and Toxicology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 20:217-30. 2010
    ....
  7. pmc Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection
    Sara Colombo
    Division of Clinical Pharmacology and Toxicology, University Hospital, CHUV, Lausanne 1011, Switzerland
    Antimicrob Agents Chemother 50:3801-8. 2006
    ..This population pharmacokinetic model, together with therapeutic drug monitoring and Bayesian dosage adaptation, can be helpful in the selection and adaptation of ATV doses...
  8. pmc Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus
    Chantal Csajka
    Division of Clinical Pharmacology, University Hospital, CHUV, Beaumont 633, Lausanne 1011, Switzerland
    Antimicrob Agents Chemother 48:3226-32. 2004
    ..The high interpatient pharmacokinetic variability represents an argument for therapeutic drug monitoring...
  9. doi request reprint Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes
    Verena Gotta
    Division of Clinical Pharmacology, Service of Biomedicine, Department of Laboratories, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, Lausanne, Switzerland
    Ther Drug Monit 35:150-67. 2013
    ..For future research, external PPK model validation or meta-model development should be considered...
  10. pmc Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals
    Mona Arab-Alameddine
    Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    Antimicrob Agents Chemother 56:2959-66. 2012
    ..Owing to the very large variability, trough drug levels might be very low under the standard dosing regimen, raising the question of a potential relevance of therapeutic drug monitoring of RAL in some situations...
  11. pmc Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir
    Manel Aouri
    Innovation and Development Laboratory, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
    Antimicrob Agents Chemother 57:3147-58. 2013
    ..This new, simple, rapid, and robust HPLC-MS/MS assay offers an efficient method of real-time TDM aimed at maximizing efficacy while minimizing the toxicity of antiviral therapy...
  12. doi request reprint Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels
    Verena Gotta
    Division of Clinical Pharmacology and Toxicology, Laboratory Department, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Clin Pharmacokinet 51:187-201. 2012
    ..In practice, however, blood sampling for TDM is often not performed at trough. The corresponding measurement is thus only remotely informative about C(min) exposure...
  13. pmc Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy
    Thierry Buclin
    Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    PLoS ONE 6:e18578. 2011
    ..We developed rules to guide frequency of CD4 cell count monitoring in HIV infection before starting antiretroviral therapy, which we validated retrospectively in patients from the Swiss HIV Cohort Study...
  14. doi request reprint In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
    Julia Di Iulio
    Institute of Microbiology Division of Clinical Pharmacology, University Hospital Center, University of Lausanne, Lausanne, Switzerland
    Pharmacogenet Genomics 19:300-9. 2009
    ..We hypothesize that genetic variability in this gene may contribute to the particularly high, unexplained variability in EFV exposure in individuals with limited CYP2B6 function...
  15. doi request reprint Benchmarking therapeutic drug monitoring software: a review of available computer tools
    Aline Fuchs
    Division of Clinical Pharmacology, Service of Biomedicine, Department of Laboratory, Hôpital de Beaumont, Centre Hospitalier Universitaire Vaudois and University of Lausanne, 1011, Lausanne, Switzerland
    Clin Pharmacokinet 52:9-22. 2013
    ..Computer-assisted TDM is gaining growing interest and should further improve, especially in terms of information system interfacing, user friendliness, data storage capability and report generation...
  16. ncbi request reprint Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents
    Margalida Rotger
    Institute of Microbiology and University Hospital, Lausanne, Switzerland
    Curr HIV/AIDS Rep 3:118-25. 2006
    ..Despite the negative perception of genetic research among the general public, this type of investigation is now widely accepted by concerned parties: patients, relatives, and study volunteers...
  17. ncbi request reprint Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
    Sandrine Ostermann
    Multidisciplinary Oncology Center, Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Clin Cancer Res 10:3728-36. 2004
    ....
  18. ncbi request reprint ADME pathway approach for pharmacogenetic studies of anti-HIV therapy
    Rubin Lubomirov
    Institute of Microbiology, University Hospital and University of Lausanne, Bugnon 48, 1011 Lausanne, Switzerland
    Pharmacogenomics 8:623-33. 2007
    ..This review compiles information for future analysis of the role of specific genes/variants in the exposure and response to antiretroviral therapy to generate a ranked list of new genetic variants for future studies...
  19. ncbi request reprint Pharmacokinetic-pharmacodynamic modelling: history and perspectives
    Chantal Csajka
    Department of Biopharmaceutical Sciences, University of California, San Francisco, CA, USA
    J Pharmacokinet Pharmacodyn 33:227-79. 2006
    ....
  20. ncbi request reprint Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects
    Chantal Csajka
    Department of Biopharmaceutical Sciences and Biostatistics, University of California, San Francisco, 94143, USA
    J Pharmacol Exp Ther 313:647-57. 2005
    ..The increase in heart rate due to CHF3381 was 0.0055 bpm/micro(g l-1). CHF3381 produces a concentration-dependent decrease in DHPG plasma concentrations, whose magnitude increased after multiple twice-a-day regimens for 14 days...